Compare FSI & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSI | BNR |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.2M | 76.5M |
| IPO Year | 2000 | 2019 |
| Metric | FSI | BNR |
|---|---|---|
| Price | $6.50 | $8.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.5K | ★ 25.3K |
| Earning Date | 04-15-2026 | 06-05-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,494,325.00 | N/A |
| Revenue This Year | $63.39 | $111.65 |
| Revenue Next Year | $43.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.61 | $3.11 |
| 52 Week High | $11.48 | $41.72 |
| Indicator | FSI | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 61.08 | 37.97 |
| Support Level | $6.28 | $8.04 |
| Resistance Level | $6.67 | $9.90 |
| Average True Range (ATR) | 0.19 | 0.83 |
| MACD | 0.01 | 0.31 |
| Stochastic Oscillator | 95.83 | 46.26 |
Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The company also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.